Alan Barge, MD, Chairman


Alan Barge trained in medicine at Oxford and London, and specialized in haematology and oncology, completing research and clinical fellowships in Seattle in 1990. Alan joined Amgen in 1990, as European Medical Director, and was responsible for the European, and subsequently Worldwide development of Neupogen® (filgrastim), and other haemapoietic growth factors. Alan has led FDA BRMAC and EMA/CHMP submissions and presentations for a number of new indications for filgrastim.

In 1999 Alan joined AstraZeneca, and was asked to establish a team, responsible for early phase oncology drug development. In 2003 Alan was made responsible for the re‐focusing of the development, and registration of Iressa® (gefitinib) in Asia, and Europe, in molecularly defined subsets of NSCLC. He was subsequently appointed VP of Clinical and Head of Oncology and Infection, responsible for building and managing a large development group, and the execution of AstraZeneca’s oncology portfolio globally. In this role, Alan was responsible for re-shaping the discovery and development groups, and for the acquisition of Kudos, which yielded the drug olaparib (Lynparza®).

Alan left AstraZeneca in 2011 and co-founded ASLAN Pharmaceuticals, a Singapore-based biopharmaceutical company which focuses on Asia-prevalent cancers.

In 2016 Alan helped found Carrick Therapeutics in the UK, which also focuses on early-stage oncology assets. He was responsible, with the CEO and CSO, for raising $95M in a combined Series A/B initial round of funding.


Anton Berns, PhD


Anton is an internationally renowned cancer scientist. In 1999, he was appointed Director of Research and Chairman of the Board of Directors of the NKI and Antoni van Leeuwenhoek Hospital. He is elected member of the Royal Netherlands Academy of Arts and Sciences, and Fellow of the American Association for Cancer Research (AACR), an honorary title granted to a select number of scientists whose work has proven to be of great importance for the advancement of cancer research. In 2016, he was elected as foreign member of the National Academy of Sciences of the US.

Anton currently heads a research group at NKI that excels in developing advanced, complex mouse models for cancer research. He obtained his PhD in biochemistry at the Radboud University in Nijmegen, the Netherlands. He joined the Netherlands Cancer Institute (NKI) as a staff scientist in 1985. In 1986, he became head of the division of Molecular Genetics. From 1992-1994 he serves as Vice President of Somatix Gene Therapy Corporation in the Bay area where under his guidance cancer vaccines were produced. 



Harry Büller, MD, PhD


Harry is Professor of Internal Medicine, specialized in Vascular Medicine at the Academic Medical Center in Amsterdam, the Netherlands. He was awarded his MD and PhD at the University of Amsterdam. He is the recipient of the Established Investigator Award presented by the Dutch Heart Foundation (1993-1998) and was honored with the Dutch Society for Vascular Medicine Award in 2005. He is Honorary Professor of the Royal Netherlands Academy of Arts and Sciences.

After graduating, he completed his research fellowship in hemostasis and thrombosis at the Departments of Medicine and Clinical Epidemiology and Biostatistics at McMaster University in Hamilton, Ontario, Canada in 1981-1982.

He has authored and coauthored more than 554 scientific articles in leading journals. He was Co-Chairman of the Amsterdam Institute for Cardiovascular Research, and is Chairman of the Vascular Medicine Working Group.



Mark Krul,  PhD


Mark has been involved in anti-cancer drug development since 1993 and has a background in molecular biology and immunology. He obtained a PhD at the University of Utrecht on the development of experimental vaccines against cancer.

Prior to co-founding  the Aglaia BioMedical Ventures/Aglaia Oncology Fund in 2003, he was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002).

From 1993-1997, Mark was Research Manager at the European Cancer Center in Amsterdam. Prior to that, he headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989-1993.



Karl Rothweiler


Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nijenrode.

Before starting up Aglaia, he was involved in the founding, restructuring and funding of multiple technology-driven companies. In 1995, he founded Entity Holding B.V., a venture company focusing on early-stage companies. Karl serves at the board of a number of life sciences companies. 


Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
Read more

Modra's Unique Approach

improving patient lives    
Learn more


Meet us at one of the following events:      
Read more